mdbrain

mediaire

mdbrain is a software solution powered by artificial intelligence (AI) for volumetric brain analysis, the characterization of white matter lesions, brain tumour characterization and brain aneurysm detection. It uses a combination of several deep learning methods to derive reliable data from MR images. The solution integrates with the PACS and provides quantitative reports. Through a browser-based platform the system can be supervised. Local installation keeps patient data within the centre.

Product specifications

Information source: Vendor
Last updated: Nov. 22, 2022

General
Product name	mdbrain
Company	mediaire
Subspeciality	Neuro
Modality	MR
Disease targeted	Dementia, NPH, multiple sclerosis, neurodegenerative diseases, vascular dementia, brain aneurysm, brain tumour
Key-features	Brain volume quantification (global, regional down to Hippocampus, ventricles), white/grey matter quantification, white matter lesion detection and progression tracking, aneurysm detection, tumour characterization
Suggested use	Before: stratifying reading process (non, single, double read) During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), interactive 3D-annotation viewer for white matter lesions
Data characteristics
Population	early diagnosis and follow up of neurodegenerative diseases like dementia and auto-immune diseases like multiple sclerosis
Input	1.5 or 3T MR by Siemens, Philips or GE
Input format	DICOM
Output	table of quantified values, tables and schematics with color coded deviations from normal database, segmentation overlay, lesion annotations, classification of lesions as MS-specific
Output format	PDF, DICOM-PDF, browser-based platform, CSV-Export file
Technology
Integration	Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker)
Trigger for analysis	Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time	1 - 10 minutes
Certification
CE	Certified, Class I , MDD
FDA	No or not yet
Market presence
On market since	01-2019
Distribution channels	QMENTA Trials, TELEPAXX, AngioNautix, Calantic
Countries present (clinical, non-research use)	3 (Germany, Switzerland & Austria)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Pay-per-use
Based on	Number of analyses
Evidence
Peer reviewed papers on performance	Automated Detection of Cerebral Aneurysms on TOF-MRA Using a Deep Learning Approach : An External Validation (read) Triplanar U-Net with lesion-wise voting for the segmentation of new lesions on longitudinal MRI studies (read)
Non-peer reviewed papers on performance
Other relevant papers